Study shows selenium-containing compounds inhibit SARS-CoV-2 replication and assembly

A recent paper by researchers from the Netherlands and Poland provides evidence that modified ebselen derivatives may serve as highly promising prospective drugs against coronavirus disease 2019 (COVID-19). The manuscript is freely available on the bioRxiv* preprint server.

In the midst of COVID-19 pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the world waits for any sign of hope in countering the disease. This can only be done by repurposing or developing effective drugs or vaccines.

Research unfolding at an unprecedented pace recently unveiled potential targets: cysteine proteases that play a significant part in the viral replication process. These structures can be actively used to search for compounds that block their action, and in turn, exert sufficient antiviral activity.

Novel Coronavirus SARS-CoV-2 Colorized scanning electron micrograph of an apoptotic cell (pink) heavily infected with SARS-COV-2 virus particles (green), isolated from a patient sample. Image captured at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland. Credit: NIAID
Novel Coronavirus SARS-CoV-2 Colorized scanning electron micrograph of an apoptotic cell (pink) heavily infected with SARS-COV-2 virus particles (green), isolated from a patient sample. Image captured at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland. Credit: NIAID

SARS-CoV-2 proteases and seleno-organic molecules

Two proteases may serve as a target for drugs: main or chymotrypsin-like protease (Mpro) responsible for polypeptide processing during viral replication, and papain-like protease (PLpro) that – alongside aiding in viral replication – assembles new virus particles within human cells.

PLpro from newly discovered SARS-CoV-2 is supposedly the essential viral enzyme that incapacitates the antiviral immune response and takes advantage of the host's immune system. Hence, the current understanding of the SARS-CoV-2 infectious process indicates that shutting off PLpro represents a viable strategy in halting the spread of the virus.

Some recent research endeavors pinpointed peptide analogs and ebselen (a synthetic seleno-organic molecule) as highly active inhibitors for PLpro. Ebselen is known for its cytoprotective, anti-inflammatory, and anti-atherosclerotic traits, also displaying a low toxicity profile. Furthermore, the compound was proved to be effective in hepatitis C and various malignancies.

This is why researchers from the University of Amsterdam and Vrije Universiteit Amsterdam in the Netherlands, as well as Wroclaw University of Science and Technology in Poland, aimed to appraise the inhibitory properties of twelve ebselen derivatives against the original SARS virus (SARS-CoV-1) PLpro (PLproSARS) and SARS-CoV-2 PLpro (PLproCoV2).

A model of the complex of compound 1d with SARS-CoV-2 PLpro
A model of the complex of compound 1d with SARS-CoV-2 PLpro

Pharmaceutical chemistry at its best

A total of twelve organoselenium compounds, i.e., structural analogs of antioxidant drug ebselen, were screened for their capacity to inhibit the aforementioned papain-like protease (PLpro) from the SARS-CoV-2.

For the enzymes assay, spectrofluorimetry (a highly sensitive analytical method that detects fluorescent compounds at the level of nanograms) was used to measure reactions in 96-well plate format using two wavelengths: excitation at 355 nanometers and emission at 460 nanometers.

For the inhibition assay, the inhibitor was screened against recombinant PLproSARS and PLproCoV2 at 37°C in the assay buffer. A total of eight different inhibitor concentrations were used, while 50% inhibition value (IC50) was taken from the dependence of the hydrolysis velocity on the logarithm of the inhibitor concentration.

Finally, molecular modeling studies were performed using the Discovery Studio 2020 (software utilized for predictions, modeling, and simulation in life sciences). The crystal structure of the SARS-CoV-2 was taken as the starting point for calculating the enzyme complexed with ebselen.

In pursuit of blockbuster derivatives

In this study, the researchers identified four potent inhibitors that show favorable binding properties towards PLpro of SARS-CoV-2. Akin to recently published articles on ebselen, the mode of action was shown to be irreversible.

Interestingly, most of the derivatives completely blocked PLproCoV2 at a high concentration of the inhibitor (20 micromoles); conversely, only five of them inhibited PLproSARS, while the rest of them failed.

"In conclusion, we identified very effective inhibitors of PLproCoV2, with the IC50 constants in the nanomolar range", explain study authors in their paper available on the bioRxiv preprint server.

"Our findings provide evidence that ebselen derivatives with an additional hydroxy or methoxy group serve as highly potential prospective drugs against COVID-19", they conclude.

In any case, the activity of the PLproCoV2 is pivotal for the progression of COVID-19; therefore, it can be perceived as a key target for the development of anti-SARS-CoV-2 drugs that may actually enter the drug pipeline in the near future.

*Important Notice

bioRxiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information.

Journal reference:
Dr. Tomislav Meštrović

Written by

Dr. Tomislav Meštrović

Dr. Tomislav Meštrović is a medical doctor (MD) with a Ph.D. in biomedical and health sciences, specialist in the field of clinical microbiology, and an Assistant Professor at Croatia's youngest university - University North. In addition to his interest in clinical, research and lecturing activities, his immense passion for medical writing and scientific communication goes back to his student days. He enjoys contributing back to the community. In his spare time, Tomislav is a movie buff and an avid traveler.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Meštrović, Tomislav. (2020, May 21). Study shows selenium-containing compounds inhibit SARS-CoV-2 replication and assembly. News-Medical. Retrieved on July 05, 2020 from https://www.news-medical.net/news/20200521/Study-shows-selenium-containing-compounds-inhibit-SARS-CoV-2-replication-and-assembly.aspx.

  • MLA

    Meštrović, Tomislav. "Study shows selenium-containing compounds inhibit SARS-CoV-2 replication and assembly". News-Medical. 05 July 2020. <https://www.news-medical.net/news/20200521/Study-shows-selenium-containing-compounds-inhibit-SARS-CoV-2-replication-and-assembly.aspx>.

  • Chicago

    Meštrović, Tomislav. "Study shows selenium-containing compounds inhibit SARS-CoV-2 replication and assembly". News-Medical. https://www.news-medical.net/news/20200521/Study-shows-selenium-containing-compounds-inhibit-SARS-CoV-2-replication-and-assembly.aspx. (accessed July 05, 2020).

  • Harvard

    Meštrović, Tomislav. 2020. Study shows selenium-containing compounds inhibit SARS-CoV-2 replication and assembly. News-Medical, viewed 05 July 2020, https://www.news-medical.net/news/20200521/Study-shows-selenium-containing-compounds-inhibit-SARS-CoV-2-replication-and-assembly.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
The approved dose of ivermectin alone not useful in treating COVID-19